GB004

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company's lead program is seralutinib (GB002), an inhaled PDGFR, CSF1R, and c-KIT inhibitor currently in Phase 3 clinical trials for the treatment of pulmonary arterial hypertension (PAH). Gossamer Bio previously developed GB004, a gut-targeted HIF-1α stabilizer for ulcerative colitis, though development for that indication was discontinued following Phase 2 results to prioritize the PAH program. The company aims to address high unmet medical needs through targeted therapies that improve patient outcomes in chronic inflammatory conditions.